8-Hydroxyquinolines: A review of their metal chelating properties and medicinal applications

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 1157-1178

  Prachayasittikul, Veda ^a   Prachayasittikul, Supaluk ^a   Ruchirawat, Somsak ^b   Prachayasittikul, Virapong ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b CHULABHORN RESEARCH INSTITUTE   (Thailand)

Author keywords

Anticancer; Antidiabetic; Antineurodegenerative; Metal binding compound; Multifunctional actions; Structure activity relationships

Indexed keywords

2 METHYL 5 (3,4,5 TRIMETHOXYBENZAMIDO)DECAHYDROISOQUINOLINE; 4 BENZENESULFONAMIDE; 5 IODOURACIL MANGANESE 8 HYDROXYQUINOLINE COMPLEX; 5 NITROSO 8 HYDROXYQUINOLINE; 8 HYDROXYQUINALDINE; 8 HYDROXYQUINOLINE GLUCOCONJUGATE; 8 HYDROXYQUINOLINE METAL COMPLEX; 8 HYDROXYQUINOLINE URACIL METAL COMPLEX; 8 QUINOLINOL; 8 QUINOLINOL DERIVATIVE; ANTIMONY; ANTIMONY 8 HYDROXYQUINOLINE COMPLEX; ARTIFICIAL CARBOHYDRATE RECEPTOR; ARTIFICIAL RECEPTOR; BENZENESULFONAMIDE DERIVATIVE; CLIOQUINOL; CLIOQUINOL GLUCOCONJUGATE; COPPER ION; HLA 20; LADOSTIGIL; MANGANESE DERIVATIVE; METAL; METAL COMPLEX; NITROXOLINE; NSC 3852; PLERIXAFOR; SULFANILAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VK 28; XANTHURINIC ACID; ZINC ION;

ALZHEIMER DISEASE; AMEBIASIS; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTINEURODEGENERATIVE ACTIVITY; ANTIOXIDANT ACTIVITY; CHELATION; DEGENERATIVE DISEASE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; HOMEOSTASIS; HUMAN; LIPOPHILICITY; METABOLIC DISORDER; METAL HOMEOSTASIS; METAL IMBALANCE; MULTIPLE SCLEROSIS; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; REVIEW; STRUCTURE ACTIVITY RELATION;

ANTICANCER; ANTIDIABETIC; ANTINEURODEGENERATIVE; METAL BINDING COMPOUND; MULTIFUNCTIONAL ACTIONS; STRUCTURE-ACTIVITY RELATIONSHIPS;

ANIMALS; CHELATING AGENTS; DRUG DESIGN; HUMANS; HYDROXYQUINOLINES; METALS; OXYQUINOLINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84885060514     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S49763     Document Type: Review

References (191)

1. Short BR, Vargas MA, Thomas JC, O'Hanlon S, Enright MC. In vitro activity of a novel compound, the metal ion chelating agent AQ1, against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 2006;57(1):104-109.
2. Albrecht M, Fiege M, Osetska O. 8-Hydroxyquinolines in metallosupramolecular chemistry. Coord Chem Rev. 2008;252(8-9):812-824.
3. Budimir A. Metal ions, Alzheimer's disease and chelation therapy. Acta Pharm. 2011;61(1):1-14.
4. Crichton RR, Dexter DT, Ward RJ. Metal based neurodegenerative diseases-From molecular mechanisms to therapeutic strategies. Coord Chem Rev. 2008;252(10-11):1189-1199.
5. Vanparia SF, Patel TS, Sojitra NA, et al. Synthesis, characterization and antimicrobial study of novel 4-{[(8-Hydroxyquinolin-5-yl)methyl]amino}benzenesulfonamide and its oxinates. Acta Chim Slov. 2010;57(3):600-667.
6. Rubbo SD, Albert A, Gibson MI. The influence of chemical constitution on antibacterial activity. V. The antibacterial action of 8-hydroxyquinoline (oxine). Br J Exp Pathol. 1950;31(3):425-441.
7. Crichton RR, Dexter DT, Ward RJ. Brain iron metabolism and its perturbation in neurological diseases. J Neural Transm. 2011;118(3):301-314.
8. Tõugu V, Palumaa P. Coordination of zinc ions to the key proteins of neurodegenerative diseases: Aβ, APP, α-synuclein and PrP. Coord Chem Rev. 2012;256(19-20):2219-2224.
9. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci. 2003;26(4):207-214.
10. Bush AI, Tanzi RE. Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics. 2008;5(3):421-432.
11. Gaeta A, Hider RC. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br J Pharmacol. 2005;146(8):1041-1059.
12. Zatta P, Drago D, Bolognin S, Sensi SL. Alzheimer's disease, metal ions and metal homeostatic therapy. Trends Pharmacol Sci. 2009;30(7): 346-355.
13. Perez LR, Franz KJ. Minding metals: tailoring multifunctional chelating agents for neurodegenerative disease. Dalton Trans. 2010;39(9): 2177-2187.
14. Crouch PJ, Barnham KJ. Therapeutic redistribution of metal ions to treat Alzheimer's disease. Acc Chem Res. 2012;45(9):1604-1611.
15. Zheng H, Gal S, Weiner LM, et al. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem. 2005;95(1):68-78.
16. Kaur D, Yantiri F, Rajagopalan S, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron. 2003;37(6):899-909.
17. Zheng H, Youdim MB, Weiner LM, Fridkin M. Synthesis and evaluation of peptidic metal chelators for neuroprotection in neurodegenerative diseases. J Pept Res. 2005;66(4):190-203.
18. Deraeve C, Pitié M, Mazarguil H, Meunier B. Bis-8-hydroxyquinoline ligands as potential anti-Alzheimer agents. New J Chem. 2007;31(2): 193-195.
19. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol. 2003;60(12):1685-1691.
20. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 2001;30(3):665-676.
21. Tateishi J. Subacute myelo-optico-neuropathy: clioquinol intoxication in humans and animals. Neuropathology. 2000;20 Suppl: S20-S24.
22. Yassin MS, Ekblom J, Xilinas M, Gottfries CG, Oreland L. Changes in uptake of vitamin B(12) and trace metals in brains of mice treated with clioquinol. J Neurol Sci. 2000;173(1):40-44.
23. Budimir A, Humbert N, Elhabiri M, Osinska I, Biruš M, Albrecht-Gary AM. Hydroxyquinoline based binders: promising ligands for chelatotherapy? J Inorg Biochem. 2011;105(3):490-496.
24. LeVine H, Ding Q, Walker JA, Voss RS, Augelli-Szafran CE. Clioquinol and other hydroxyquinoline derivatives inhibit Abeta (1-42) oligomer assembly. Neurosci Lett. 2009;465(1):99-103.
25. White AR, Du T, Laughton KM, et al. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem. 2006;281(26):17670-17680.
26. Adlard PA, Cherny RA, Finkelstein DI, et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron. 2008;59(1):43-55.
27. Crouch PJ, Savva MS, Hung LW, et al. The Alzheimer's therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity. J Neurochem. 2011;119(1):220-230.
28. Adlard PA, Bica L, White AR, et al. Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease. PLoS One. 2011;6(3):e17669.
29. Lannfelt L, Blennow K, Zetterberg H, et al; PBT2-201-EURO study group. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2008;7(9):779-786.
30. Faux NG, Ritchie CW, Gunn A, et al. PBT2 rapidly Improves cognition in Alzheimer's disease: additional Phase II analyses. J Alzheimers Dis. 2010;20(2):509-516.
31. Crouch PJ, Tew DJ, Du T, et al. Restored degradation of the Alzheimer's amyloid-beta peptide by targeting amyloid formation. J Neurochem. 2009;108(5):1198-1207.
32. Gal S, Fridkin M, Amit T, Zheng H, Youdim MBH. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease. J Neural Transm Suppl. 2006;(70):447-456.
33. Kasarskis EJ, Tandon L, Lovell MA, Ehmann WD. Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser microprobe mass spectroscopy: a preliminary study. J Neurol Sci. 1995;130(2):203-208.
34. Pollak Y, Mechlovich D, Amit T, et al. Effects of novel neuroprotective and neurorestorative multifunctional drugs on iron chelation and glucose metabolism. J Neural Transm. 2013;120(1):37-48.
35. Riederer P, Sofic E, Rausch WD, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem. 1989;52(2):515-520.
36. Paris I, Martinez-Alvarado P, Cárdenas S, et al. Dopamine-dependent iron toxicity in cells derived from rat hypothalamus. Chem Res Toxicol. 2005;18(3):415-419.
37. Zheng H, Weiner LM, Bar-Am O, et al. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem. 2005;13(3):773-783.
38. Avramovich-Tirosh Y, Amit T, Bar-Am O, Zheng H, Fridkin M, Youdim MB. Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J Neurochem. 2007;100(2):490-502.
39. Avramovich-Tirosh Y, Bar-Am O, Amit T, Youdim MB, Weinreb O. Up-regulation of hypoxia-inducible factor (HIF)-1α and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30. Curr Alzheimer Res. 2010;7(4):300-306.
40. Kupershmidt L, Weinreb O, Amit T, Mandel S, Carri MT, Youdim MB. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. 2009;23(11): 3766-3779.
41. Weinreb O, Mandel S, Bar-Am O, Amit T. Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim. J Neural Transm. 2011;118(3):479-492.
42. Youdim MB, Weinstock M. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Neurotoxicology. 2004;25(1-2): 243-250.
43. Stevens RG, Kalkwarf DR. Iron, radiation, and cancer. Environ Health Perspect. 1990;87:291-300.
44. Brem S. Angiogenesis and cancer control: from concept to therapeutic trial. Cancer Control. 1999;6(5):436-458.
45. Brewer GJ. Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Exp Biol Med (Maywood). 2001;226(7):665-673.
46. Theophanides T, Anastassopoulou J. Copper and carcinogenesis. Crit Rev Oncol Hematol. 2002;42(1):57-64.
47. Daniel KG, Harbach RH, Guida WC, Dou QP. Copper storage diseases: Menkes, Wilsons, and cancer. Front Biosci. 2004;9:2652-2662.
48. Gupte A, Mumper RJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev. 2009;35(1): 32-46.
49. Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999; 341(26):1986-1995.
50. Le NT, Richardson DR. The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta. 2002;1603(1): 31-46.
51. Halliwell B, Gutteridge JM, Cross CE. Free radicals, antioxidants, and human disease: where are we now? J Lab Clin Med. 1992;119(6): 598-620.
52. Cerutti PA. Oxy-radicals and cancer. Lancet. 1994;344(8926): 862-863.
53. Leanderson P, Tagesson C. Rapid and sensitive detection of hydroxyl radicals formed by activated neutrophils in the presence of chelated iron: hydroxylation of deoxyguanosine to 8-hydroxydeoxyguanosine. Agents Actions. 1992;36(1-2):50-57.
54. Leanderson P, Tagesson C. Iron bound to the lipophilic iron chelator, 8-hydroxyquinoline, causes DNA strand breakage in cultured lung cells. Carcinogenesis. 1996;17(3):545-550.
55. Jonas SK, Riley PA. The effect of ligands on the uptake of iron by cells in culture. Cell Biochem Funct. 1991;9(4):245-253.
56. Schraufstatter IU, Hinshaw DB, Hyslop PA, Spragg RG, Cochrane CG. Oxidant injury of cells. DNA strand-breaks activate polyadenosine diphosphate-ribose polymerase and lead to depletion of nicotinamide adenine dinucleotide. J Clin Invest. 1986;77(4):1312-1320.
57. Zhou ZH, Ando S, Furutsuka D, Ikebe M. Characterization of Ca2+/calmodulin-dependent protein kinase II from smooth muscle. Biochem J. 1995;310(Pt 2):517-525.
58. Hecht SM. DNA strand scission by activated bleomycin group antibiotics. Fed Proc. 1986;45(12):2784-2791.
59. Shaw AY, Chang CY, Hsu MY, et al. Synthesis and structure-activity relationship study of 8-hydroxyquinoline-derived Mannich bases as anticancer agents. Eur J Med Chem. 2010;45(7):2860-2867.
60. Lescoat G, Léonce S, Pierré A, Gouffier L, Gaboriau F. Antiproliferative and iron chelating efficiency of the new bis-8-hydroxyquinoline benzylamine chelator S1 in hepatocyte cultures. Chem Biol Interact. 2012;195(2):165-172.
61. Moor EC. In methods in enzymology. In: Colowick SP, Kaplan ND, editors. Method in Enzymology. New York, NY: Academic; 1967;(12 Pt A):155.
62. Yamato M, Hashigaki K, Yasumoto Y, et al. Synthesis and antitumor activity of tropolone derivatives. 6. Structure-activity relationships of antitumor-active tropolone and 8-hydroxyquinoline derivatives. J Med Chem. 1987;30(10):1897-1900.
63. Prachayasittikul S, Worachartcheewan A, Pingaew R, et al. Metal complexes of uracil derivatives with cytotoxicity and superoxide scavenging activity. Lett Drug Des Dis. 2012;9(3):282-287.
64. Boerner LJ, Zaleski JM. Metal complex-DNA interactions: from transcription inhibition to photoactivated cleavage. Curr Opin Chem Biol. 2005;9(2):135-144.
65. Colak A, Terzi Ü, Col M, et al. DNA binding, antioxidant and antimicrobial activities of homo-and heteronuclear copper(II) and nickel(II) complexes with new oxime-type ligands. Eur J Med Chem. 2010;45(11): 5169-5175.
66. Mathur S, Tabassum S. New homodi-and heterotrinuclear metal complexes of Schiff base compartmental ligand: Interaction studies of copper complexes with calf thymus DNA. Cent Eur J Chem. 2006;4(3):502-522.
67. Cowan JA. Chemical nucleases. Curr Opin Chem Biol. 2001;5(6): 634-642.
68. Tan J, Wang B, Zhu L. DNA binding, cytotoxicity, apoptotic inducing activity, and molecular modeling study of quercetin zinc(II) complex. Bioorg Med Chem. 2009;17(2):614-620.
69. Dixit RB, Patel TS, Vanparia SF, Kunjadiya AP, Keharia HR, Dixit BC. DNA-binding interaction studies of microwave assisted synthesized sulfonamide substituted 8-hydroxyquinoline derivatives. Sci Pharm. 2011;79(2):293-308.
70. Xu H, Zheng KC, Chen Y, et al. Effects of ligand planarity on the interaction of polypyridyl Ru(II) complexes with DNA. Dalton Trans. 2003;11:2260-2268.
71. Delaney S, Pascaly M, Bhattacharya PK, Han K, Barton JK. Oxidative damage by ruthenium complexes containing the dipyridophenazine ligand or its derivatives: a focus on intercalation. Inorg Chem. 2002;41(7):1966-1974.
72. Siddiqi ZA, Khalid M, Kumar S, Shahid M, Noor S. Antimicrobial and SOD activities of novel transition metal complexes of pyridine-2,6-dicarboxylic acid containing 4-picoline as auxiliary ligand. Eur J Med Chem. 2010;45(1):264-269.
73. Serbest K, Colak A, Güner S, Karaböcek S, Kormali F. Copper(II)-manganese(II) complexes of 3,3′-(1,3-propanediyldiimine)bis-(3-methyl-2-butanone)dioxime with superoxide dismutase-like activity. Transit Metal Chem. 2001;26(6):625-629.
74. Saheki T, Ueda A, Hosoya M, et al. Qualitative and quantitative abnormalities of argininosuccinate synthetase in citrullinemia. Clin Chim Acta. 1981;109(3):325-335.
75. Nayak SB, Bhat VR, Upadhyay D, Udupa SL. Copper and ceruloplasmin status in serum of prostate and colon cancer patients. Indian J Physiol Pharmacol. 2003;47(1):108-110.
76. Huang YL, Sheu JY, Lin TH. Association between oxidative stress and changes of trace elements in patients with breast cancer. Clin Biochem. 1999;32(2):131-136.
77. Rizk SL, Sky-Peck HH. Comparison between concentrations of trace elements in normal and neoplastic human breast tissue. Cancer Res. 1984;44(11):5390-5394.
78. Turecký L, Kalina P, Uhliková E, Námerová S, Krizko J. Serum ceruloplasmin and copper levels in patients with primary brain tumors. Klin Wochenschr. 1984;62(4):187-189.
79. Chen D, Cui QC, Yang H, et al. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Res. 2007;67(4):1636-1644.
80. Ding WQ, Lind SE. Metal ionophores-an emerging class of anticancer drugs. IUBMB Life. 2009;61(11):1013-1018.
81. Daniel KG, Chen D, Orlu S, Cui QC, Miller FR, Dou QP. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res. 2005;7(6):R897-R908.
82. Mao X, Li X, Sprangers R, et al. Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma. Leukemia. 2009;23(3):585-590.
83. Lind SE, Park JS, Drexler JW. Pyrithione and 8-hydroxyquinolines transport lead across erythrocyte membranes. Transl Res. 2009;154(3): 153-159.
84. Ding WQ, Liu B, Vaught JL, Yamauchi H, Lind SE. Anticancer activity of the antibiotic clioquinol. Cancer Res. 2005;65(8):3389-3395.
85. Yu H, Zhou Y, Lind SE, Ding WQ. Clioquinol targets zinc to lysosomes in human cancer cells. Biochem J. 2009;417(1):133-139.
86. Andersson DA, Gentry C, Moss S, Bevan S. Clioquinol and pyrithione activate TRPA1 by increasing intracellular Zn2+. Proc Natl Acad Sci U S A. 2009;106(20):8374-8379.
87. Ruschak AM, Slassi M, Kay LE, Schimmer AD. Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst. 2011;103(13):1007-1017.
88. Geraki K, Farquharson MJ, Bradley DA. Concentrations of Fe, Cu and Zn in breast tissue: a synchrotron XRF study. Phys Med Biol. 2002;47(13):2327-2339.
89. Dìez M, Cerdàn FJ, Arroyo M, Balibrea JL. Use of the copper/zinc ratio in the diagnosis of lung cancer. Cancer. 1989;63(4):726-730.
90. Yoshida D, Ikeda Y, Nakazawa S. Quantitative analysis of copper, zinc and copper/zinc ratio in selected human brain tumors. J Neurooncol. 1993;16(2):109-115.
91. Daniel KG, Gupta P, Harbach RH, Guida WC, Dou QP. Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochem Pharmacol. 2004;67(6):1139-1151.
92. Dorkin TJ, Neal DE. Basic science aspects of prostate cancer. Semin Cancer Biol. 1997;8(1):21-27.
93. Arnold JT, Isaacs JT. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer. 2002;9(1):61-73.
94. Yu H, Lou JR, Ding WQ. Clioquinol independently targets NF-kappaB and lysosome pathways in human cancer cells. Anticancer Res. 2010;30(6):2087-2092.
95. Ding WQ, Yu HJ, Lind SE. Zinc-binding compounds induce cancer cell death via distinct modes of action. Cancer Lett. 2008;271(2):251-259.
96. Jiang H, Taggart JE, Zhang X, Benbrook DM, Lind SE, Ding WQ. Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline). Cancer Lett. 2011;312(1):11-17.
97. Arbiser JL, Kraeft SK, van Leeuwen R, et al. Clioquinol-zinc chelate: a candidate causative agent of subacute myelo-optic neuropathy. Mol Med. 1998;4(10):665-670.
98. American Academy of Pediatrics Committee on Drugs: Clioquinol (iodochlorhydroxyquin, vioform) and iodoquinol (diiodohydroxyquin): blindness and neuropathy. Pediatrics. 1990;86(5):797-798.
99. Oliveri V, Giuffrida ML, Vecchio G, Aiello C, Viale M. Gluconjugates of 8-hydroxyquinolines as potential anti-cancer prodrugs. Dalton Trans. 2012;41(15):4530-4535.
100. Kawamura T, Kusakabe T, Sugino T, et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001;92(3):634-641.
101. Arafa HM. Possible contribution of beta-glycosidases and caspases in the cytotoxicity of novel glycoconjugates in colon cancer cells. Invest New Drugs. 2010;28(3):306-317.
102. Pavlov A, Takuchev N, Georgieva N. Drug design by regression analyses of newly synthesized derivatives of 8-quinolinol. Biotechnol Biotechnol Equip. 2011;26(1):164-169.
103. Jeon JH, Lee CH, Lee HS. Antimicrobial activities of 2-methyl-8-hydroxyquinoline and its derivatives against human intestinal bacteria. J Korean Soc Appl Biol Chem. 2009;52(2):202-205.
104. Ahmed SM, Ismail DA. Synthesis and biological activity of 8-hydroxyquinoline and 2-hydroxypyridine quaternary ammonium salts. J Surfact Deterg. 2008;11(3):231-235.
105. Strobl JS, Seibert CW, Li Y, et al. Inhibition of Toxoplasma gondii and Plasmodium falciparum infections in vitro by NSC3852, a redox active antiproliferative and tumor cell differentiation agent. J Parasitol. 2009;95(1):215-223.
106. Scheibel LW, Adler A. Antimalarial activity of selected aromatic chelators. III. 8-Hydroxyquinolines (oxines) substituted in positions 5 and 7, and oxines annelated in position 5,6 by an aromatic ring. Mol Pharmacol. 1982;22(1):140-144.
107. Madrid PB, Sherrill J, Liou AP, Weisman JL, Derisi JL, Guy RK. Synthesis of ring-substituted 4-aminoquinolines and evaluation of their antimalarial activities. Bioorg Med Chem Lett. 2005;15(4): 1015-1018.
108. Moret V, Dereudre-Bosquet N, Clayette P, et al. Synthesis and anti-HIV properties of new hydroxyquinoline-polyamine conjugates on cells infected by HIV-1 LAV and HIV-1 BaL viral strains. Bioorg Med Chem Lett. 2006;16(23):5988-5992.
109. Darby CM, Nathan CF. Killing of non-replicating Mycobacterium tuberculosis by 8-hydroxyquinoline. J Antimicrob Chemother. 2010;65(7):1424-1427.
110. Warner VD, Musto JD, Sane JN, Kim KH, Grunewald GL. Quantitative structure-activity relationships for 5-substituted 8-hydroxyquinolines as inhibitors of dental plaque. J Med Chem. 1977;20(1):92-96.
111. Tanzer JM, Slee AM, Kamay B, Scheer E. Activity of three 8-hydroxyquinoline derivatives against in vitro dental plaque. Antimicrob Agents Chemother. 1978;13(6):1044-1045.
112. Ananthan S, Faaleolea ER, Goldman RC, et al. High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb). 2009;89(5):334-353.
113. Kharadi GJ, Patel JR, Dholakiya BZ. Antituberculosis, antifungal and thermal activity of mixed ligand transition metal complexes. Appl Organomet Chem. 2010;24(11):821-827.
114. Irish D, Eltringham I, Teall A, et al. Control of an outbreak of an epidemic methicillin-resistant Staphylococcus aureus also resistant to mupirocin. J Hosp Infect. 1998;39(1):19-26.
115. Takahashi N. Microbial ecosystem in the oral cavity: metabolic diversity in an ecological niche and its relationship with oral diseases. Proceedings of the International Symposium for Interface Oral Health, Sendai, Japan, 2-3 February 2005; International Congress Series. 2005;1284:103-112.
116. Rathsam C, Eaton RE, Simpson CL, et al. Two-dimensional fluorescence difference gel electrophoretic analysis of Streptococcus mutans biofilms. J Proteome Res. 2005;4(6):2161-2173.
117. Lemos JA, Abranches J, Burne RA. Responses of cariogenic streptococci to environmental stresses. Curr Issues Mol Biol. 2005;7(1): 95-107.
118. Albert A, Magrath D. The choice of a chelating agent for inactivating trace metals: II. Derivatives of oxine (8-hydroxyquinoline). Biochem. J. 1947;41(4):534-530.
119. Albert A, Gibson MI, Rubbo SD. The influence of chemical constitution on antibacterial activity. VI. The bactericidal action of 8-hydroxyquinoline (oxine). Br J Exp Pathol. 1953;34(2):119-130.
120. Anjaneyulu Y, Rao RP, Swamy RY, Eknath A, Rao KN. In vitro antimicrobial-activity studies on the mixed ligand complexes of Hg(II) with 8-hydroxyquinoline and salicylic acids. Proc Indian Acad Sci (Chem Sci). 1982;91(2):157-163.
121. Srisung S, Suksrichavalit T, Prachayasittikul S, Ruchirawat S, Prachayasittikul V. Antimicrobial activity of 8-hydroxyquinoline and transition metal complexes. Int J Pharmacol. 2013:9(2)170-175.
122. Shen AY, Chen CP, Roffler S. A chelating agent possessing cytotoxicity and antimicrobial activity: 7-morpholinomethyl-8-hydroxyquinoline. Life Sci. 1999;64(9):813-825.
123. Badawi AM, Mohamed MA, Mohamed MZ, Khowdairy MM. Surface and antitumor activity of some novel metal-based cationic surfactants. J Cancer Res Ther. 2007;3(4):198-206.
124. Rohde W, Mikelens P, Jackson J, Blackman J, Whitcher J, Levinson W. Hydroxyquinolines inhibit ribonucleic acid-dependent deoxyribonucleic acid polymerase and inactivate Rous sarcoma virus and herpes simplex virus. Antimicrob Agents Chemother. 1976;10(2): 234-240.
125. Auld DS, Kawaguchi H, Livingston DM, Vallee BL. RNA-dependent DNA polymerase (reverse transcriptase) from avian myeloblastosis virus: a zinc metalloenzyme. Proc Natl Acad Sci U S A. 1974;71(5): 2091-2095.
126. Valenzuela P, Morris RW, Faras A, Levinson W, Rutter WJ. Are all nucleotidyl transferases metalloenzymes? Biochem Biophys Res Commun. 1973;53(3):1036-1041.
127. Albert A. Quantitative studies of the avidity of naturally occurring substances for trace metals. III. Pteridines, riboflavin and purines. Biochem J. 1953;54(4):646-654.
128. De Clercq E. Antiviral drug discovery and development: where chemistry meets with biomedicine. Antiviral Res. 2005;67(2):56-75.
129. De Clercq E. HIV-chemotherapy and-prophylaxis: new drugs, leads and approaches. Int J Biochem Cell Biol. 2004;36(9):1800-1822.
130. Hatse S, Princen K, Gerlach LO, et al. Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. Mol Pharmacol. 2001;60(1): 164-173.
131. Gilles HM. Management of Severe Malaria: A Practical Handbook. 2nd ed. Geneva: World Health Organization; 2000.
132. Coatney GR, Cooper WC, Eddy NB, Greengerg J. Survey of antimalarial agents: chemotherapy of Plasmodium gallinaceum infections; toxicity; correlation of structure and action. Public Health Monogr. 1953;9:1-322.
133. De D, Krogstad FM, Cogswell FB, Krogstad DJ. Aminoquinolines that circumvent resistance in Plasmodium falciparum in vitro. Am J Trop Med Hyg. 1996;55(6):579-583.
134. Scheibel LW, Adler A, Trager W. Tetraethylthiuram disulfide (Antabuse) inhibits the human malaria parasite Plasmodium falciparum. Proc Nat Acad Sci U S A. 1979;76(10):5303-5307.
135. Scheibel LW, Adler A. Antimalarial activity of selected aromatic chelators. Mol Pharmacol. 1980;18(2):320-325.
136. Scheibel LW, Adler A. Antimalarial activity of selected aromatic chelators. II. Substituted quinolines and quinoline-N-oxides. Mol Pharmacol. 1981;20(1):218-223.
137. Owens RG. Studies on the nature of fungicidal action. I. Inhibition of sulfhydryl-, amino-, iron-, and copper-dependent enzymes in vitro by fungicides and related compounds. Contr Boyce Thompson Inst. 1953;17(3):221-242.
138. Denton H, Roberts CW, Alexander J, Thong KW, Coombs GH. Enzymes of energy metabolism in the bradyzoites and tachyzoites of Toxoplasma gondii. FEMS Microbiol Lett. 1996;137(1):103-108.
139. McCarthy SM, Davis CD. Prooxidant diet provides protection during murine infection with Toxoplasma gondii. J Parasitol. 2003;89(5): 886-894.
140. Pino P, Foth BJ, Kwok LY, et al. Dual targeting of antioxidant and metabolic enzymes to the mitochondrion and the apicoplast of Toxoplasma gondii. PLoS Pathog. 2007;3(8):e115.
141. Martirosyan A, Leonard S, Shi X, Griffith B, Gannett P, Strobl J. Actions of a histone deacetylase inhibitor NSC3852 (5-nitroso-8-quinolinol) link reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells. J Pharmacol Exp Ther. 2006;317(2):546-552.
142. Henry TR, Wallace KB. Differential mechanisms of cell killing by redox cycling and arylating quinones. Arch Toxicol. 1996;70(8):482-489.
143. Reis DC, Pinto MC, Souza-Fagundes EM, et al. Investigation on the pharmacological profile of antimony(III) complexes with hydroxyquinoline derivatives: anti-trypanosomal activity and cytotoxicity against human leukemia cell lines. Biometals. 2011;24(4):595-601.
144. Halliwell B, Gutteridge JM. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J. 1984;219(1):1-14.
145. Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. Curr Med Chem. 2005;12(10):1161-1208.
146. Mau JL, Lin HC, Song SF. Antioxidant properties of several specialty mushrooms. Food Res Int. 2002;35(6):519-526.
147. Roby MHH, Sarhan MA, Selim KAH, Khalel KI. Evaluation of antioxidant activity, total phenols and phenolic compounds in thyme (Thymus vulgaris L.), sage (Salvia officinalis L.), and marjoram (Origanum majorana L.) extracts. Ind Crops Prod. 2013;43:827-831.
148. Ma L, Liu Z, Zhou B, Yang L, Liu Z. Inhibition of free radical induced oxidative hemolysis of red blood cells by green tea polyphenols. Chin Sci Bull. 2000;45(22):2052-2056.
149. Prachayasittikul V, Prachayasittikul S, Ruchirawat S. High therapeutic potential of Spilanthes acmella: A review. EXCLI J. 2013;12:291-312.
150. Burton GW, Ingold KU. Vitamin E: application of the principles of physical organic chemistry to the exploration of its structure and function. Acc Chem Res. 1986;19(7):194-201.
151. Spiteller G. Linoleic acid peroxidation-the dominant lipid peroxidation process in low density lipoprotein-and its relationship to chronic diseases. Chem Phys Lipids. 1998;95(2):105-162.
152. Mechlovich D, Amit T, Mandel SA, et al. The novel multifunctional, iron-chelating drugs M30 and HLA20 protect pancreatic beta-cell lines from oxidative stress damage. J Pharmacol Exp Ther. 2010;333(3): 874-882.
153. Fernández-Bachiller MI, Pérez C, González-Muñoz GC, et al. Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties. J Med Chem. 2010;53(13):4927-4937.
154. Çolak AT, Çolak F, Yeşilel OZ, Büyükgüngör O. Synthesis, spectroscopic, thermal, voltammetric studies and biological activity of crystalline complexes of pyridine-2,6-dicarboxylic acid and 8-hydroxyquinoline. J Mol Struct. 2009;936(1-3):67-74.
155. Czapski G, Goldstein S. Requirements for SOD mimics operating in vitro to work also in vivo. Free Radic Res Commun. 1991;12-13(Pt 1):167-171.
156. Wang Y, Yang ZY, Wang BD. Synthesis, characterization and anti-oxidative activity of cobalt(II), nickel(II) and iron(II) Schiff base complexes. Transit Metal Chem. 2005;30:879-883.
157. Suksrichavalit T, Prachayasittikul S, Nantasenamat C, Isarankura-Na-Ayudhya C, Prachayasittikul V. Copper complexes of pyridine derivatives with superoxide scavenging and antimicrobial activities. Eur J Med Chem. 2009;44(8):3259-3265.
158. Suksrichavalit T, Prachayasittikul S, Piacham T, Isarankura-Na-Ayudhya C, Nantasenamat C, Prachayasittikul V. Copper complexes of nicotinic-aromatic carboxylic acids as superoxide dismutase mimetics. Molecules. 2008;13(12):3040-3056.
159. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol. 1997;15:323-350.
160. Kim YH, Woo KJ, Lim JH, et al. 8-Hydroxyquinoline inhibits iNOS expression and nitric oxide production by down-regulating LPS-induced activity of NF-kappaB and C/EBPbeta in Raw 264.7 cells. Biochem Biophys Res Commun. 2005;329(2):591-597.
161. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J. 2001;357(Pt 3):593-615.
162. Rao KM. Molecular mechanisms regulating iNOS expression in various cell types. J Toxicol Environ Health B Crit Rev. 2000;3(1):27-58.
163. Lee AK, Sung SH, Kim YC, Kim SG. Inhibition of lipopolysaccharide-inducible nitric oxide synthase, TNF-alpha and COX-2 expression by sauchinone effects on I-kappaBalpha phosphorylation, C/EBP and AP-1 activation. Br J Pharmacol. 2003;139(1):11-20.
164. Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem. 1994;269(7):4705-4708.
165. Hu H, Shih R, Rothenberg S, Schwartz BS. The epidemiology of lead toxicity in adults: measuring dose and consideration of other methodologic issues. Environ Health Perspect. 2007;115(3):455-462.
166. Kosnett MJ, Becker CE, Osterloh JD, Kelly TJ, Pasta DJ. Factors influencing bone lead concentration in a suburban community assessed by noninvasive K x-ray fluorescence. JAMA. 1994;271(3):197-203.
167. Menke A, Muntner P, Batuman V, Silbergeld EK, Guallar E. Blood lead below 0.48 micromol/L (10 microg/dL) and mortality among US adults. Circulation. 2006;114(13):1388-1394.
168. Shih RA, Hu H, Weisskopf MG, Schwartz BS. Cumulative lead dose and cognitive function in adults: a review of studies that measured both blood lead and bone lead. Environ Health Perspect. 2007;115(3): 483-492.
169. Weisskopf MG, Proctor SP, Wright RO, et al. Cumulative lead exposure and cognitive performance among elderly men. Epidemiology. 2007;18(1):59-66.
170. Bergdahl IA, Grubb A, Schütz A, et al. Lead binding to delta-aminolevulinic acid dehydratase (ALAD) in human erythrocytes. Pharmacol Toxicol. 1997;81(4):153-158.
171. Paglia DE, Valentine WN, Dahlgren JG. Effects of low-level lead exposure on pyrimidine 5′-nucleotidase and other erythrocyte enzymes. Possible role of pyrimidine 5′-nucleotidase in the pathogenesis of lead-induced anemia. J Clin Invest. 1975;56(5):1164-1169.
172. Boas FE, Forman L, Beutler E. Phosphatidylserine exposure and red cell viability in red cell aging and in hemolytic anemia. Proc Nat Acad Sci U S A. 1998;95(6):3077-3081.
173. Chiu D, Lubin B, Roelofsen B, van Deenen LL. Sickled erythrocytes accelerate clotting in vitro: an effect of abnormal membrane lipid asymmetry. Blood. 1981;58(2):398-401.
174. Shin JH, Lim KM, Noh JY, et al. Lead-induced procoagulant activation of erythrocytes through phosphatidylserine exposure may lead to thrombotic diseases. Chem Res Toxicol. 2007;20(1):38-43.
175. Rogan WJ, Dietrich KN, Ware JH, et al; Treatment of Lead-Exposed Children Trial Group. The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. N Eng J Med. 2001;344(19):1421-1426.
176. Hamidinia SA, Erdahl WL, Chapman CJ, Steinbaugh GE, Taylor RW, Pfeiffer DR. Monensin improves the effectiveness of meso-dimercaptosuccinate when used to treat lead intoxication in rats. Environ Health Perspect. 2006;114(4):484-493.
177. Sakai T, Yanagihara S, Kunugi Y, Ushio K. Mechanisms of ALA-D inhibition by lead and of its restoration by zinc and dithiothreitol. Br J Ind Med. 1983;40(1):61-66.
178. Meredith PA, Moore MR, Goldberg A. Effects of aluminium, lead and zinc on delta-aminolevulinic acid dehydratase. Enzyme. 1977;22(1): 22-27.
179. Jin S, Cheng Y, Reid S, Li M, Wang B. Carbohydrate recognition by boronolectins, small molecules, and lectins. Med Res Rev. 2010;30(2): 171-257.
180. Phillips MD, Fyles TM, Barwell NP, James TD. Carbohydrate sensing using a fluorescent molecular tweezer. Chem Commun (Camb). 2009;43:6557-6559.
181. Ardá A, Venturi C, Nativi C, et al. A chiral pyrrolic tripodal receptor enantioselectively recognizes beta-mannose and beta-mannosides. Chemistry. 2010;16(2):414-418.
182. Davis AP. Synthetic lectins. Org Biomol Chem. 2009;7(18): 3629-3638.
183. Mazik M, Geffert C. 8-Hydroxyquinoline as a building block for artificial receptors: binding preferences in the recognition of glycopyranosides. Org Biomol Chem. 2011;9(7):2319-2326.
184. Melnik B, John SM, Schmitz G. Over-stimulation of insulin/IGF-1 signaling by western diet may promote diseases of civilization: lessons learnt from Laron syndrome. Nutr Metab (Lond). 2011;8(1):41.
185. Cheng Z, White MF. Targeting forkhead box O1 from the concept to metabolic diseases: lessons from mouse models. Antioxid Redox Signal. 2011;14(4):649-661.
186. Salih DA, Brunet A. FoxO transcription factors in the maintenance of cellular homeostasis during aging. Curr Opin Cell Biol. 2008;20(2): 126-136.
187. Buteau J, Accili D. Regulation of pancreatic beta-cell function by the forkhead protein FoxO1. Diabetes Obes Metab. 2007;9(Suppl 2):140-146.
188. Rains JL, Jain SK. Oxidative stress, insulin signaling, and diabetes. Free Radic Biol Med. 2011;50(5):567-575.
189. Cameron AR, Anil S, Sutherland E, Harthill J, Rena G. Zinc-dependent effects of small molecules on the insulin-sensitive transcription factor FOXO1a and gluconeogenic genes. Metallomics. 2010;2(3): 195-203.
190. Cameron AR, Wallace K, Logie L, et al. The anti-neurodegenerative agent clioquinol regulates the transcription factor FOXO1a. Biochem J. 2012;443(1):57-64.
191. Kitamura T, Nakae J, Kitamura Y, et al. The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth. J Clin Invest. 2002;110(12):1839-1847.